IRD Valuation
Opus Genetics Inc
$
1.280
- Overview
- Forecast
- Valuation
- Earnings
IRD Relative Valuation
IRD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IRD is overvalued; if below, it's undervalued.
Historical Valuation
Opus Genetics Inc (IRD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.43 is considered Undervalued compared with the five-year average of -1.37. The fair price of Opus Genetics Inc (IRD) is between 2.26 to 2.71 according to relative valuation methord. Compared to the current price of 1.24 USD , Opus Genetics Inc is Undervalued By 45.37%.
Relative Value
Fair Zone
2.26-2.71
Current Price：1.24
45.37%
Undervalued
-2.16
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Opus Genetics Inc. (IRD) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.04. The thresholds are as follows: Strongly Undervalued below -0.22, Undervalued between -0.22 and -0.09, Fairly Valued between 0.18 and -0.09, Overvalued between 0.18 and 0.31, and Strongly Overvalued above 0.31. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.08
EV/EBIT
Opus Genetics Inc. (IRD) has a current EV/EBIT of -1.08. The 5-year average EV/EBIT is -0.37. The thresholds are as follows: Strongly Undervalued below -1.37, Undervalued between -1.37 and -0.87, Fairly Valued between 0.13 and -0.87, Overvalued between 0.13 and 0.63, and Strongly Overvalued above 0.63. The current Forward EV/EBIT of -1.08 falls within the Undervalued range.
6.43
PS
Opus Genetics Inc. (IRD) has a current PS of 6.43. The 5-year average PS is 3.06. The thresholds are as follows: Strongly Undervalued below 0.15, Undervalued between 0.15 and 1.60, Fairly Valued between 4.51 and 1.60, Overvalued between 4.51 and 5.96, and Strongly Overvalued above 5.96. The current Forward PS of 6.43 falls within the Strongly Overvalued range.
-1.80
P/OCF
Opus Genetics Inc. (IRD) has a current P/OCF of -1.80. The 5-year average P/OCF is -4.45. The thresholds are as follows: Strongly Undervalued below -10.63, Undervalued between -10.63 and -7.54, Fairly Valued between -1.36 and -7.54, Overvalued between -1.36 and 1.72, and Strongly Overvalued above 1.72. The current Forward P/OCF of -1.80 falls within the Historic Trend Line -Fairly Valued range.
-1.58
P/FCF
Opus Genetics Inc. (IRD) has a current P/FCF of -1.58. The 5-year average P/FCF is -1.07. The thresholds are as follows: Strongly Undervalued below -1.49, Undervalued between -1.49 and -1.28, Fairly Valued between -0.86 and -1.28, Overvalued between -0.86 and -0.65, and Strongly Overvalued above -0.65. The current Forward P/FCF of -1.58 falls within the Strongly Undervalued range.
Opus Genetics Inc (IRD) has a current Price-to-Book (P/B) ratio of 4.22. Compared to its 3-year average P/B ratio of 3.43 , the current P/B ratio is approximately 22.94% higher. Relative to its 5-year average P/B ratio of 3.43, the current P/B ratio is about 22.94% higher. Opus Genetics Inc (IRD) has a Forward Free Cash Flow (FCF) yield of approximately -41.38%. Compared to its 3-year average FCF yield of -38.47%, the current FCF yield is approximately 7.58% lower. Relative to its 5-year average FCF yield of -38.47% , the current FCF yield is about 7.58% lower.
4.22
P/B
Median3y
3.43
Median5y
3.43
-41.38
FCF Yield
Median3y
-38.47
Median5y
-38.47
Competitors Valuation Multiple
The average P/S ratio for IRD's competitors is 45.58, providing a benchmark for relative valuation. Opus Genetics Inc Corp (IRD) exhibits a P/S ratio of 6.43, which is -85.90% above the industry average. Given its robust revenue growth of 159.17%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IRD decreased by 6.11% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 1.11M to 2.88M.
The secondary factor is the Margin Expansion, contributed -63.13%to the performance.
Overall, the performance of IRD in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Opus Genetics Inc (IRD) currently overvalued or undervalued?
Opus Genetics Inc (IRD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.43 is considered Undervalued compared with the five-year average of -1.37. The fair price of Opus Genetics Inc (IRD) is between 2.26 to 2.71 according to relative valuation methord. Compared to the current price of 1.24 USD , Opus Genetics Inc is Undervalued By 45.37% .
What is Opus Genetics Inc (IRD) fair value?
How does IRD's valuation metrics compare to the industry average?
What is the current P/B ratio for Opus Genetics Inc (IRD) as of Sep 03 2025?
What is the current FCF Yield for Opus Genetics Inc (IRD) as of Sep 03 2025?
What is the current Forward P/E ratio for Opus Genetics Inc (IRD) as of Sep 03 2025?